US20080300230A1 - Use of extracts of the genus cimicifuga as organoselective medicines for treating diseases of the genitourinary tract caused by sex hormones - Google Patents

Use of extracts of the genus cimicifuga as organoselective medicines for treating diseases of the genitourinary tract caused by sex hormones Download PDF

Info

Publication number
US20080300230A1
US20080300230A1 US12/191,426 US19142608A US2008300230A1 US 20080300230 A1 US20080300230 A1 US 20080300230A1 US 19142608 A US19142608 A US 19142608A US 2008300230 A1 US2008300230 A1 US 2008300230A1
Authority
US
United States
Prior art keywords
medicament
cimicifuga
extract
cimicifuga species
species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/191,426
Inventor
Wolfgang Wuttke
Hubertus Jarry
Volker Christoffel
Barbara Spengler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionorica SE
Original Assignee
Bionorica SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionorica SE filed Critical Bionorica SE
Priority to US12/191,426 priority Critical patent/US20080300230A1/en
Assigned to THE BIONORICA AG reassignment THE BIONORICA AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHRISTOFFEL, VOLKER, WUTTKE, WOLFGANG, SPENGLER, BARBARA, JARRY, HUBERTUS
Publication of US20080300230A1 publication Critical patent/US20080300230A1/en
Priority to US13/305,323 priority patent/US20120071501A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Definitions

  • the present invention relates to a use of extracts from Cimicifuga species.
  • 17 ⁇ -estradiol which is formed in women's ovaries (any mention of estradiol hereinbelow refers to physiological 17 ⁇ -estradiol) [hereinafter also referred to as E 2 ], has a generally proliferation-enhancing effect in the organism.
  • E 2 physiological 17 ⁇ -estradiol
  • estradiol as well as the male sexual hormone testosterone also have a proliferation-enhancing effect in the bladder and in the prostate.
  • cystitis frequently develops in the post-menopausal woman as a consequence of reduced mucous membrane in the urethra and thus facilitated ascension of germs.
  • Urinary-incontinence frequently occurring post-menopausally is equally caused by lack of estrogen. These disorders may be prevented or alleviated, respectively, by timely administration of estradiol.
  • estrogens having a nonselective proliferative action is particularly adverse for uterus and breast tissue, for uncontrolled growth may occur here owning to the insufficiency or lack of gestagen counter-regulation.
  • the present invention relates to
  • Cimicifuga racemosa extract for example from the rhizoma of Cimicifuga racemosa , also has effects similar to those of estradiol in both the urinary bladder and in the urethra of ovarectomized rats.
  • the bladder both the estrogen receptor ER-alpha and ER-beta are expressed.
  • estradiol and Cimicifuga analogously regulate down the expression of the estrogen receptor-alpha in the urinary bladder.
  • the bladder tonus may also be influenced through steroid hormones.
  • FIG. 1 shows a diagram which represents the differential bladder tonus of ovarectomized rats (group sizes: 12 animals). Following a three-month treatment of ovarectomized rats with Cimicifuga racemosa extract, the maximum pressure in the urinary bladder [in mm Hg] and the minimum pressure [in mm Hg] following relaxation of the bladder were determined by instillation of 1 ml of physiological saline solution.
  • the diagram in accordance with FIG. 1 shows on the ordinate the differential pressure [in mm Hg] between maximum and minimum pressure, which is an indication for the elasticity of the urinary bladder.
  • estradiol is found to be the most effective substance.
  • the highest Cimicifuga dose 400 mg/kg/d triggers an effect comparable to that of the synthetic SERM (Selective Estrogen Receptor Modulator), Raloxifen.
  • Benign prostate hyperplasy and prostate carcinoma in men may also be influenced favorably by inhibition of the local estrogen production, but also by inhibiting synthesis of the male sexual hormones.
  • estradiol and the Cimicifuga extract significantly inhibit gene expression of the estrogen receptor of the alpha-subtype in the prostate without having an effect on the gene expression of the estrogen receptor-beta.
  • Cimicifuga racemosa extracts have an anti-androgenic favorably influencing prostate carcinoma and significantly inhibiting growth of the tumor cells in vitro.
  • extract used in accordance with the invention are suited for producing a ready-formulated medicament for the selective treatment and/or prophylaxis of sexual hormone-related disorders of the uro-genital tract.
  • ingredients or groups of ingredients to be particularly taken into consideration are the following: triterpenes, e.g., acteol and cimicigenol derivatives; polyphenols, such as caffeic acid and its derivatives, chlorogenic acid, piscidic acid, fucinolic acid, ferulic and isoferulic acid, cimicifugic acids; formononetine; alkaloids, e.g. cytisine and methylcytisine.
  • Cimicifuga racemosa these ingredients are, besides in Cimicifuga racemosa , also found in additional Cimicifuga species such as, e.g., C. foetida, C. dahurica, C. heracleifolia, C. simplex, C. japonica, C. europaea, C. acerina, C. elata, C. rubifolia.
  • Cimicifuga species may thus also be used for producing extracts, and thus medicaments against the sexual hormone-related disorders of the uro-genital tract that are being mentioned in the context of the present invention.
  • rhizoma roots, stalks, leaves and/or petals of the plants are used for producing the extracts.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

The present invention relates to extracts from Cimicifuga species and particularly from Cimicifuga racemosa, which are suited for producing a ready-formulated drug for the selective treatment and/or prophylaxis of sexual hormone-related disorders of the uro-genital tract. The extracts in accordance with the invention are moreover suited for the treatment and/or prophylaxis of post-menopausal urinary bladder infections. They are furthermore indicated for the treatment of benign and malignant prostate hyperplasies.

Description

  • The present application is a divisional application of U.S. patent application Ser. No. 10/490,190, filed Sep. 13, 2004 as a national stage under 35 U.S.C. 371(c) of PCT Application Serial No. PCT/EP02/10383, filed Sep. 16, 2002, which in turn claimed priority from German Patent Application Serial No. 10146159.3, filed Sep. 19, 2001. Priority is hereby claimed from these previous applications, including U.S. patent application Ser. No. 10/490,190, PCT Application Serial No. PCT/EP02/10383, and German Patent Application Serial No. 10146159.3.
  • The present invention relates to a use of extracts from Cimicifuga species.
  • It is known from WO 99/47 149 (+EP 1064009A 1) to the applicant of the present application that extracts from Cimicifuga racemosa have an estrogenic not on the uterus, however in the hypothalamo-hypophysary axis, in the cardiovascular system, and in the bone. Insofar extracts from Cimicifuga racemosa have been utilized in order to produce an estrogen-type, organoselective medicament having no uterotrophic effect.
  • 17β-estradiol, which is formed in women's ovaries (any mention of estradiol hereinbelow refers to physiological 17β-estradiol) [hereinafter also referred to as E2], has a generally proliferation-enhancing effect in the organism. In addition to controlling the female cycle it i.a. also has a homeostatic effect on the functions of urethra, bladder, and vagina. In men, locally formed estradiol as well as the male sexual hormone testosterone also have a proliferation-enhancing effect in the bladder and in the prostate.
  • During menopause, lowering of the estradiol level takes place due to cessation of the ovarial function. This results in weakening of proliferative processes in many organs, with subsequently occurring degeneration and reduced functional capacity.
  • With lack of estrogen, cystitis frequently develops in the post-menopausal woman as a consequence of reduced mucous membrane in the urethra and thus facilitated ascension of germs.
  • Urinary-incontinence frequently occurring post-menopausally is equally caused by lack of estrogen. These disorders may be prevented or alleviated, respectively, by timely administration of estradiol.
  • Hormonal regulation of the function of the bladder in men presumably is similar to that in women; in any case the hitherto known regulative principles in the urinary bladder of male and female rats are very similar.
  • The administration of estrogens having a nonselective proliferative action is particularly adverse for uterus and breast tissue, for uncontrolled growth may occur here owning to the insufficiency or lack of gestagen counter-regulation.
  • Up to the present, there is no medicament available from plant drugs that might be used for an organoselective prophylaxis or therapy of changes in the uro-genital tract in the event of estrogen deficiency.
  • Starting out from this prior art, it accordingly is an object of the present invention to furnish plant medicaments having a sexual hormone-type action while having an organoselective action with no effect or only little effect on the uterus.
  • This object is achieved through the use of extracts from Cimicifuga species, particularly Cimicifuga racemosa.
  • In particular; the present invention relates to
      • use of extracts from Cimicifuga species, particularly Cimicifuga racemosa, for producing an estrogen-type organoselective medicament having no uterotrophic effect or one that is at least negligible, wherein the medicament is used for alleviating sexual hormone-related disorders of the uro-genital tract.
      • Use is preferred in the following, post-menopausally occurring disorders: cystitis and dry vagina.
      • Moreover the present invention relates to a use of extracts from Cimicifuga species, particularly Cimicifuga racemosa, for producing an estrogen-type organoselective medicament having no uterotrophic effect or one that is at least negligible, wherein
      • the medicament is utilized for alleviating benign and malignant prostate hyperplasy.
  • It was surprisingly found that Cimicifuga racemosa extract, for example from the rhizoma of Cimicifuga racemosa, also has effects similar to those of estradiol in both the urinary bladder and in the urethra of ovarectomized rats. In the bladder both the estrogen receptor ER-alpha and ER-beta are expressed. It was found that estradiol and Cimicifuga analogously regulate down the expression of the estrogen receptor-alpha in the urinary bladder. Thus it appears that besides innervation, the bladder tonus may also be influenced through steroid hormones.
  • FIG. 1 shows a diagram which represents the differential bladder tonus of ovarectomized rats (group sizes: 12 animals). Following a three-month treatment of ovarectomized rats with Cimicifuga racemosa extract, the maximum pressure in the urinary bladder [in mm Hg] and the minimum pressure [in mm Hg] following relaxation of the bladder were determined by instillation of 1 ml of physiological saline solution.
    •
  • The diagram in accordance with FIG. 1 shows on the ordinate the differential pressure [in mm Hg] between maximum and minimum pressure, which is an indication for the elasticity of the urinary bladder.
  • In comparison with placebo controls following a treatment with Cimicifuga extract, a significant dosage-dependent increase of bladder elasticity, measured through the pressure difference between relaxed and definedly filled bladder, is found.
  • In the test system, estradiol is found to be the most effective substance. The highest Cimicifuga dose (400 mg/kg/d) triggers an effect comparable to that of the synthetic SERM (Selective Estrogen Receptor Modulator), Raloxifen.
  • Thus an additional effect of the extract on the urinary bladder, namely, an improvement of bladder incontinence, is equally proven.
  • Benign prostate hyperplasy and prostate carcinoma in men may also be influenced favorably by inhibition of the local estrogen production, but also by inhibiting synthesis of the male sexual hormones.
  • The like active mechanisms may also be demonstrated on the male castrated rat for the Cimicifuga racemosa extract. In the course of trials by the inventors of the present application, it was found that estradiol and the Cimicifuga extract significantly inhibit gene expression of the estrogen receptor of the alpha-subtype in the prostate without having an effect on the gene expression of the estrogen receptor-beta.
  • Both in in-vivo experiments in the rat prostate in the whole-body model and in human prostate carcinoma cells it was surprisingly found that Cimicifuga racemosa extracts have an anti-androgenic favorably influencing prostate carcinoma and significantly inhibiting growth of the tumor cells in vitro.
  • In the prostate of castrated male rats, gene expression of the proliferation-enhancing growth factor IGF1 is moreover regulated up by testosterone, however regulated down by Cimicifuga, as is desired for reducing the hyperplasy. The prostate regression induced by castration could be antagonized in the rat by testosterone. In analogy with the findings in the case of castrated rats not treated with androgen (see above), the IGF1 expression regulated up by testosterone (see above) could also be regulated down by the Cimicifuga extract. These findings clearly demonstrate that the testosterone-induced prostate growth may be inhibited by extracts from Cimicifuga species.
  • In experiments on the human prostate-Ca line LNCAP, 5 alpha-dihydrotestosterone-induced proliferation and the production of its prostate-specific antigen (PSA) may significantly be inhibited by Cimicifuga species, particularly Cimicifuga racemosa.
  • Inasmuch as IGF1 always participated in the proliferation not only of benign but also malignant tumors, the inhibitory effect of extracts from Cimicifuga species on IGF1-gene expression in conjunction with this finding is evidence for an inhibitory effect on the prostate carcinoma.
  • As regards manufacture of the extract in accordance with the invention, WO99/47 149 is herewith fully included herein by reference, the essential features of which are, however, presently summarized as follows:
  • It was found through in-vitro and in-vivo experimentation that extracts produced both from Cimicifuga species, particularly Cimicifuga racemosa, with organic solvents or mixtures of organic solvents with water or with supercritical CO2 have an organoselective effect on the uro-genital system, with an effect on the uterus being absent.
  • Thus the extract used in accordance with the invention are suited for producing a ready-formulated medicament for the selective treatment and/or prophylaxis of sexual hormone-related disorders of the uro-genital tract.
  • Furthermore they are suitable for producing a ready-formulated medicament for the selective treatment and/or prophylaxis of post-menopausal urinary bladder infections.
  • They are moreover suited for producing a ready-formulated medicament for the treatment of benign and malignant prostate hyperplasies.
  • It was moreover found that enriched and/or pure ingredients or groups of ingredients from Cimicifuga species essentially have the same effects as the whole extract.
  • Ingredients or groups of ingredients to be particularly taken into consideration are the following: triterpenes, e.g., acteol and cimicigenol derivatives; polyphenols, such as caffeic acid and its derivatives, chlorogenic acid, piscidic acid, fucinolic acid, ferulic and isoferulic acid, cimicifugic acids; formononetine; alkaloids, e.g. cytisine and methylcytisine.
  • These ingredients are, besides in Cimicifuga racemosa, also found in additional Cimicifuga species such as, e.g., C. foetida, C. dahurica, C. heracleifolia, C. simplex, C. japonica, C. europaea, C. acerina, C. elata, C. rubifolia.
  • These further Cimicifuga species may thus also be used for producing extracts, and thus medicaments against the sexual hormone-related disorders of the uro-genital tract that are being mentioned in the context of the present invention.
  • Preferably rhizoma, roots, stalks, leaves and/or petals of the plants are used for producing the extracts.

Claims (22)

1. A method for alleviating a sexual hormone-related disorder of the uro-genital tract comprising the step of administering an estrogen-type organoselective medicament having at most a negligible uterotrophic effect, the medicament comprising an extract from a Cimicifuga species.
2. The method of claim 1 wherein the sexual hormone-related disorder of the uro-genital tract is a post-menopausally occurring disorder.
3. The method of claim 2 wherein the post-menopausally occurring disorder is selected from the group consisting of urinary bladder infection and dry vagina.
4. The method of claim 3 wherein the Cimicifuga species is selected from the group consisting of: C. racemosa, C. foetida, C. dahurica, C. heracleifolia, C. simplex, C. japonica, C. europaea, C. acerina, C. elata, C. rubifolia.
5. The method of claim 4 wherein the Cimicifuga species is C. racemosa.
6. The method of claim 1 wherein the extract is produced from a Cimicifuga species by extraction with an organic solvent.
7. The method of claim 1 wherein the extract is produced from a Cimicifuga species by extraction with a mixture of an organic solvent and water.
8. The method of claim 1 wherein the extract is produced from a Cimicifuga species by extraction with supercritical CO2.
9. An estrogen-type organoselective medicament having at most a negligible uterotrophic effect, the medicament comprising an extract from a Cimicifuga species, the medicament alleviating a sexual hormone-related disorder of the uro-genital tract when administered.
10. The medicament of claim 9 wherein the sexual hormone-related disorder of the uro-genital tract is a post-menopausally occurring disorder.
11. The medicament of claim 10 wherein the post-menopausally occurring disorder is selected from the group consisting of urinary bladder infection and dry vagina.
12. The medicament of claim 9 wherein the Cimicifuga species is selected from the group consisting of: C. racemosa, C. foetida, C. dahurica, C. heracleifolia, C. simplex, C. japonica, C. europaea, C. acerina, C. elata, C. rubifolia.
13. The medicament of claim 12 wherein the Cimicifuga species is C. racemosa.
14. The medicament of claim 9 wherein the extract is produced from a Cimicifuga species by extraction with an organic solvent.
15. The medicament of claim 9 wherein the extract is produced from a Cimicifuga species by extraction with a mixture of an organic solvent and water.
16. The medicament of claim 9 wherein the extract is produced from a Cimicifuga species by extraction with supercritical CO2.
17. An estrogen-type organoselective medicament, the medicament comprising an extract from a Cimicifuga species, the medicament alleviating a prostatic disorder selected from the group consisting of benign and malignant prostate hyperplasy.
18. The medicament of claim 17 wherein the Cimicifuga species is selected from the group consisting of: C. racemosa, C. foetida, C. dahurica, C. heracleifolia, C. simplex, C. japonica, C. europaea, C. acerina, C. elata, C. rubifolia.
19. The medicament of claim 18 wherein the Cimicifuga species is C.
20. The medicament of claim 17 wherein the extract is produced from a Cimicifuga species by extraction with an organic solvent.
21. The medicament of claim 17 wherein the extract is produced from a Cimicifuga species by extraction with a mixture of an organic solvent and water.
22. The medicament of claim 17 wherein the extract is produced from a Cimicifuga species by extraction with supercritical CO2.
US12/191,426 2001-09-19 2008-08-14 Use of extracts of the genus cimicifuga as organoselective medicines for treating diseases of the genitourinary tract caused by sex hormones Abandoned US20080300230A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/191,426 US20080300230A1 (en) 2001-09-19 2008-08-14 Use of extracts of the genus cimicifuga as organoselective medicines for treating diseases of the genitourinary tract caused by sex hormones
US13/305,323 US20120071501A1 (en) 2001-09-19 2011-11-28 Use of extracts of the genus cimicifuga as organoselective medicines for treating diseases of the genitourinary tract caused by sex hormones

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10146159.3 2001-09-19
DE10146159A DE10146159A1 (en) 2001-09-19 2001-09-19 Use of extracts from Cimicifuga species as an organ-selective drug for the treatment of sex hormone-dependent diseases of the urogenital tract
PCT/EP2002/010383 WO2003024465A2 (en) 2001-09-19 2002-09-16 Use of extracts of the genus cimicifuga as organoselective medicines
US10/490,190 US7413754B2 (en) 2001-09-19 2002-09-16 Use of extracts of the genus Cimicifugaas organoselective medicines for treating diseases of the genitourinary system caused by sex hormones
US12/191,426 US20080300230A1 (en) 2001-09-19 2008-08-14 Use of extracts of the genus cimicifuga as organoselective medicines for treating diseases of the genitourinary tract caused by sex hormones

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2002/010383 Division WO2003024465A2 (en) 2001-09-19 2002-09-16 Use of extracts of the genus cimicifuga as organoselective medicines
US10/490,190 Division US7413754B2 (en) 2001-09-19 2002-09-16 Use of extracts of the genus Cimicifugaas organoselective medicines for treating diseases of the genitourinary system caused by sex hormones

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/305,323 Continuation US20120071501A1 (en) 2001-09-19 2011-11-28 Use of extracts of the genus cimicifuga as organoselective medicines for treating diseases of the genitourinary tract caused by sex hormones

Publications (1)

Publication Number Publication Date
US20080300230A1 true US20080300230A1 (en) 2008-12-04

Family

ID=7699541

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/490,190 Expired - Fee Related US7413754B2 (en) 2001-09-19 2002-09-16 Use of extracts of the genus Cimicifugaas organoselective medicines for treating diseases of the genitourinary system caused by sex hormones
US12/191,426 Abandoned US20080300230A1 (en) 2001-09-19 2008-08-14 Use of extracts of the genus cimicifuga as organoselective medicines for treating diseases of the genitourinary tract caused by sex hormones
US13/305,323 Abandoned US20120071501A1 (en) 2001-09-19 2011-11-28 Use of extracts of the genus cimicifuga as organoselective medicines for treating diseases of the genitourinary tract caused by sex hormones

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/490,190 Expired - Fee Related US7413754B2 (en) 2001-09-19 2002-09-16 Use of extracts of the genus Cimicifugaas organoselective medicines for treating diseases of the genitourinary system caused by sex hormones

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/305,323 Abandoned US20120071501A1 (en) 2001-09-19 2011-11-28 Use of extracts of the genus cimicifuga as organoselective medicines for treating diseases of the genitourinary tract caused by sex hormones

Country Status (16)

Country Link
US (3) US7413754B2 (en)
EP (1) EP1427430B1 (en)
JP (1) JP2005503404A (en)
KR (1) KR20040041619A (en)
AT (1) ATE293985T1 (en)
AU (1) AU2002362365A1 (en)
BR (1) BR0212598A (en)
DE (2) DE10146159A1 (en)
DK (1) DK1427430T3 (en)
EA (1) EA006164B1 (en)
ES (1) ES2238631T3 (en)
MX (1) MXPA04002592A (en)
PL (1) PL206937B1 (en)
PT (1) PT1427430E (en)
UA (1) UA78228C2 (en)
WO (1) WO2003024465A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1745796A1 (en) 2005-07-19 2007-01-24 Bionorica Research GmbH Compound preparation for treating prostate carcinoma
DE102007044916A1 (en) 2007-09-19 2009-04-23 Bionorica Ag Cosmetic or dermatological composition for topical use
MD4025C2 (en) * 2009-08-25 2010-10-31 Владимир КАРАУШ Remedy for treating prostatitis and prostate hyperplasia
KR101303693B1 (en) 2011-06-30 2013-09-04 한국식품연구원 Compositions for Improving Lipid Metabolism Disease, Menopause Disease or Cardiovascular Disease
JP2013010796A (en) * 2012-10-15 2013-01-17 Kao Corp Control agent for expression of s100a8
IT201900000343A1 (en) * 2019-01-10 2020-07-10 Herbal E Antioxidant Derivatives S R L Ed In Forma Abbreviata H&Ad S R L COMPOSITIONS FOR THE TREATMENT OF MENOPAUSE, OSTEOPENIA AND OSTEOPOROSIS, METABOLIC AND VASCULAR DISORDERS RELATED TO CLIMATER

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050037100A1 (en) * 1998-03-19 2005-02-17 Bionorica Ag Utilization of extracts from iris plants, cimicifuga racemose and tectorigenin as an estrogen-like organ-selective medicament without uterotropic

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6330417A (en) 1986-07-23 1988-02-09 Tsumura Juntendo Inc Anti-allergic agent
HU204197B (en) 1986-10-30 1991-12-30 Dr Papay Valeria Tothne Process for producing extract for treating aphta, herpes, wounds in the mouth, acne, comedo and pustule
EP0384798B1 (en) * 1989-02-06 1993-08-11 Gen-Ichiro Soma Limulus test-positive plant glycolipid, and method of stimulating the immuno system of an animal
US5716646A (en) * 1990-05-01 1998-02-10 Smith; Steven A. Methods and compositions for treating arthritis
US5411733A (en) * 1992-04-27 1995-05-02 Hozumi; Toyoharu Antiviral agent containing crude drug
CN1090498A (en) 1993-02-01 1994-08-10 杨芳林 Lady's oral contraception Chinese patent medicine and preparation method
JP3294694B2 (en) 1993-11-15 2002-06-24 一丸ファルコス株式会社 Cell activator containing oat extract and its application
JP3501832B2 (en) 1993-11-15 2004-03-02 一丸ファルコス株式会社 Testosterone 5α-reductase inhibitor containing rhubarb extract and its application
US5569459A (en) * 1995-02-15 1996-10-29 Bio-Virus Research Incorporated Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders
JPH0930977A (en) 1995-07-20 1997-02-04 Tsuneo Nanba Therapeutic agent for bone disease containing extract of black cohosh root
RU2188029C2 (en) * 1995-09-07 2002-08-27 Л'Ореаль Application of extract out of nonphotosynthetic bacterium and extract-containing composition
ES2132855T3 (en) 1995-09-07 1999-08-16 Oreal EXTRACT OF IRIDACEAS AND COMPOSITIONS THAT CONTAIN IT.
US6008208A (en) * 1995-10-23 1999-12-28 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
SE9503775L (en) 1995-10-26 1997-04-27 Caravan Mill Ab Technical procedure for drying, crushing and grinding mussel and seashells
US5916565A (en) * 1996-03-08 1999-06-29 In Clover, Inc. Product and method for treating joint disorders in vertebrates
CN1159340A (en) 1996-03-11 1997-09-17 李城林 Prescription of anticancer and tumor-inhibiting medicine and its preparing process
JPH107580A (en) 1996-06-15 1998-01-13 Michio Yoshida Collagenase inhibitor
JP3665848B2 (en) 1996-09-18 2005-06-29 木村 幸代 Fermented beverage of Himeogi dwarf bulb extract and method for producing the same
CN1057690C (en) 1996-10-18 2000-10-25 宁振峰 Chinese Patent medicine
DE19652183C1 (en) 1996-12-14 1998-02-12 Schaper & Bruemmer Gmbh Treating oestrogen-dependent tumour with Cimicifuga racemosa extract
US5952374A (en) * 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
US6039290A (en) 1998-03-16 2000-03-21 Honeywell Inc. Robust singularity avoidance in satellite attitude control
DE19812204A1 (en) * 1998-03-19 1999-11-04 Plantamed Arzneimittel Gmbh Use of extracts from Cimicifuga racemosa and Belamcanda sinensis as an estrogen-like organ-selective drug without uterotropic effects
US6242012B1 (en) * 1999-10-19 2001-06-05 Thomas Newmark Herbal composition for promoting hormonal balance in women and methods of using same
US20010025059A1 (en) * 2000-01-10 2001-09-27 Kastke Floyd A. Composition and method for treating non-bacterial prostatitis
US20020010141A1 (en) * 2000-03-31 2002-01-24 Jonathan Ingram Isoflavones for treatment of obesity
JP2002043945A (en) 2000-07-19 2002-02-08 Sony Corp Digital signal coder and method, digital signal decoder and method and digital signal transmission system
US6326366B1 (en) * 2000-08-22 2001-12-04 Protein Technologies International Hormone replacement therapy
DE10054641A1 (en) * 2000-11-03 2002-05-16 Schaper & Bruemmer Gmbh Use of a preparation of Cimicifuga racemosa
US20020172732A1 (en) * 2001-03-21 2002-11-21 Wies Ter Laak Composition comprising cocoa

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050037100A1 (en) * 1998-03-19 2005-02-17 Bionorica Ag Utilization of extracts from iris plants, cimicifuga racemose and tectorigenin as an estrogen-like organ-selective medicament without uterotropic

Also Published As

Publication number Publication date
PT1427430E (en) 2005-08-31
EA006164B1 (en) 2005-10-27
US7413754B2 (en) 2008-08-19
EP1427430A2 (en) 2004-06-16
EP1427430B1 (en) 2005-04-27
JP2005503404A (en) 2005-02-03
ATE293985T1 (en) 2005-05-15
PL370370A1 (en) 2005-05-16
DE10146159A1 (en) 2003-04-10
PL206937B1 (en) 2010-10-29
MXPA04002592A (en) 2005-08-26
AU2002362365A1 (en) 2003-04-01
ES2238631T3 (en) 2005-09-01
US20120071501A1 (en) 2012-03-22
US20050019437A1 (en) 2005-01-27
KR20040041619A (en) 2004-05-17
DE50202941D1 (en) 2005-06-02
BR0212598A (en) 2004-10-13
WO2003024465A3 (en) 2003-10-09
WO2003024465A2 (en) 2003-03-27
DK1427430T3 (en) 2005-05-30
EA200400461A1 (en) 2004-08-26
UA78228C2 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
EP3673905B1 (en) Composition containing cannabidiol and cannabidivarin and application of composition in treatment of dysmenorrhea
US20120071501A1 (en) Use of extracts of the genus cimicifuga as organoselective medicines for treating diseases of the genitourinary tract caused by sex hormones
AU774568B2 (en) Use of a serenoa repens extract for the production of a medicament to treat prostate cancer
US5708038A (en) Method of using aloe vera as a biological vehicle
CN103877247B (en) Medicine being used for the treatment of decubital ulcer and preparation method thereof
US20040176310A1 (en) Use of extracts and preparations from iris plants and tectorigenin as medicaments
CN113768975A (en) Traditional Chinese medicine composition for treating arthralgia, traditional Chinese medicine patch, and preparation method and use method thereof
WO2001064229A1 (en) A medicine for treating obesity and the method of producing thereof
CN113318180A (en) A Chinese medicinal composition for treating traumatic injury, and its preparation method
CN111643511A (en) Application of sophoricoside in preparing medicine for preventing and treating prostate disease
US7563464B1 (en) Treatment of mucosal membranes utilizing phytoestrogen
JP2010100547A (en) Agent for reducing or preventing side effect of hormone therapy and agent for suppressing or preventing recurrence of dysmenorrhea after hormone therapy
CN114081879B (en) New medical application of safflower Xiaoyao preparation monomer active ingredient
CN110464752A (en) A kind of Chinese medicine composition that dispelling body odour and its ointment and preparation method
RU2672061C2 (en) Remedy for treatment of chronic endometritis at stage of rehabilitation
CN114558090B (en) Medicine for treating benign prostatic hyperplasia
CN115252742B (en) A Chinese medicinal oral preparation for treating traumatic injury and fracture
CN112237621B (en) Traditional Chinese medicine emulsifiable paste for hyperplasia of mammary glands and preparation method thereof
RU2145231C1 (en) Method for treating the cases of endometriosis
RO137749A2 (en) Dietary supplements recommended for attenuation of unpleasant menopausal symptoms, preparation process and processes for determining their biosafety and biological effectivenes
TWI351970B (en) Long-acting chinese medicine formula reduce inflam
CN113318152A (en) External composition for regulating estrogen secretion and preparation method and application thereof
CN113456729A (en) Traditional Chinese medicine composition for treating acne and application thereof
Lieberman Black cohosh for menopausal symptoms
WO2018005618A1 (en) Tripartite combination therapy for prostate cancer

Legal Events

Date Code Title Description
AS Assignment

Owner name: THE BIONORICA AG, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHRISTOFFEL, VOLKER;WUTTKE, WOLFGANG;JARRY, HUBERTUS;AND OTHERS;REEL/FRAME:021662/0050;SIGNING DATES FROM 20080723 TO 20080906

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION